Abstract: Disclosed are a fully human broad-spectrum neutralizing antibody against coronavirus, and the use thereof. Specifically disclosed are a fully human monoclonal antibody against an S2 region of coronavirus S protein, a nucleic acid sequence encoding the antibody, and a preparation method therefor. The antibody can effectively bind to and neutralize a variety of coronaviruses in a broad spectrum manner, and can be used for preventing and treating diseases related to coronavirus infection, such as SARS-CoV-2. Further disclosed is the potential use thereof in vaccine design.

Abstract: A chimeric antigen receptor, includes an extracellular domain, a transmembrane domain, and an intracellular domain, which are connected in sequence, where the extracellular domain includes an antigen recognition region and a hinge region, and one end of the intracellular domain which is connected to the transmembrane domain is connected to a CD3? intracellular region. The chimeric antigen receptor can further improve the treatment effect of B-cell leukemia lymphoma, and reduce inflammatory cytokines generated from macrophage mononuclear cell activation by down-regulating cytokines, so that cytokine storm can be prevented in an early stage, and the risk of neurotoxicity can be reduced. The treatment effect of mesothelin high-expression solid tumors is further improved in mesothelin-positive tumor treatment, and the prevention of cytokine storm and the reduced risk of neurotoxicity can be realized at an early stage.

Abstract: Provided are a method for inducing differentiated cells into pluripotent endoderm stem cells and an application thereof. Specifically, provided is a method for inducing human differentiated cells to differentiate into induced pluripotent endoderm stem cells (smEnSC), comprising the step of: (a) culturing differentiated cells in a culture system under a first culture condition to obtain induced pluripotent endoderm stem cells (smEnSC), the culture system comprising EGF, A83-01, and CHIR99021. Functional induced pluripotent endodermal stem cells have a high differentiation rate and purity.

Abstract: A chimeric antigen receptor containing a CD3? intracellular region with a Y/F mutation, includes an extracellular domain, a transmembrane domain, and an intracellular domain which are connected in sequence, where one end of the intracellular domain, which is connected to the transmembrane domain, is connected to the CD3? intracellular region with the Y/F mutation, and the CD3? intracellular region with the Y/F mutation refers to a Y/F mutant CD3? intracellular region in which both tyrosines are mutated to phenylalanines in the ITAM of the CD3? intracellular region. T cells modified with the chimeric antigen receptor have improved viability, decreased apoptosis level, and increased proliferation ability, and down-regulate the expression levels of cytokines IFN-? and TNF-?.

Abstract: The present invention provides an application of CST1 in prevention and/or treatment of liver immune dysregulation diseases. Specifically, the present invention provides an application of a CST1 gene, or a protein thereof, or a promoter thereof for preparing a composition or a preparation. The composition or the preparation is used for prevention and/or treatment of liver immune dysregulation diseases.

Abstract: The present disclosure relates to methods and compositions for the treatment of cancer using an ACAT1 inhibitor. The cancer may be any of melanoma, lymphoma, esophageal cancer, liver cancer, head and neck cancer, bladder cancer, endometrial cancer, kidney cancer and thyroid cancer. In some embodiments, the cancer itself it not responsive directly to the ACAT1 inhibitor but is rather treated through the immune system activated by the ACAT1 inhibitor. Combination therapies are also provided, for instance in combination with an alkylating antineoplastic agent.

Abstract: Use of ginkgolide A in the treatment of autism. Specifically, the present invention relates to use of ginkgolide A, a stereoisomer thereof, a crystal form thereof, a pharmaceutically acceptable salt thereof, a derivative thereof, an extract comprising ginkgolide A, or a combination thereof in the preparation of a pharmaceutical composition for the treatment of autism. The experiments have demonstrated that ginkgolide A can significantly alleviate the behavioral defects of autism, and ginkgolide A has the advantages of small dosage and high safety when treating autism, and is very suitable as a common medicine for the treatment of autism.

Abstract: The present invention provides use of a circular RNA with an incomplete double-stranded structure of 16 bp-33 bp in length and/or a promoting agent of the circular RNA with an incomplete double-stranded structure of 16 bp-33 bp in length in preparation of a medicament for treating systemic lupus erythematosus.

Abstract: The present invention relates to an AG-haESCs in which H19 DMR and IG-DMR are knocked out, a method for preparing the AG-haESCs, and use of the AG-haESCs in constructing a genetically modified semi-cloned animal and a library of a genetically modified semi-cloned animal. The AG-haESCs is capable of obtaining characteristics resembling a round spermatid, and upon injection into an oocyte, a viable SC mouse is stably obtained. The present invention is capable of being effectively used in multi-gene genetic manipulation, advancing the acquisition of animals with multiple genetic modifications.